GLP-1 Eligibility: Common Disqualifiers

Demand for GLP-1 weight loss medications in Singapore has increased sharply over the past two years. More telehealth clinics now offer semaglutide and tirzepatide, and more patients are asking their doctors about Ozempic and Wegovy. But not everyone is eligible. Roughly 15-20% of patients who enquire about GLP-1 treatment have a condition that either rules them out entirely or requires extra caution before prescribing.

Knowing the disqualifiers before your consultation saves time and sets realistic expectations. Some are absolute (your doctor cannot prescribe GLP-1 under any circumstances), and some are conditional (your doctor can prescribe with adjustments and monitoring). This article covers both categories, with the specific conditions and the reasoning behind each one.

Absolute disqualifiers: when GLP-1 is not an option

These conditions rule out GLP-1 treatment entirely. No dose adjustment or monitoring protocol changes this.

Personal or family history of medullary thyroid carcinoma (MTC)

This is the most well-known GLP-1 contraindication. It carries an FDA boxed warning, the most serious category of drug safety alert.

In animal studies, GLP-1 receptor agonists caused thyroid C-cell tumours in rodents at high doses. Whether this translates to humans is still unknown, but the risk is serious enough that regulators worldwide prohibit GLP-1 prescriptions for anyone with a personal or family history of medullary thyroid carcinoma (MTC). The same applies if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN2), a genetic condition that predisposes you to MTC.

For context, MTC accounts for only 3-4% of all thyroid cancers. Most thyroid cancer diagnoses are papillary thyroid carcinoma, which is not a contraindication. If you have had thyroid cancer, the specific type matters. Your doctor will ask about this during your consultation.

History of pancreatitis

If you have had pancreatitis, especially recurrent or unexplained episodes, GLP-1 medications are contraindicated. GLP-1 medications slow gastric emptying and affect pancreatic secretion, which can trigger inflammation in a pancreas with a prior history of problems.

Clinical trial data shows acute pancreatitis occurred in roughly 0.1-0.2% of semaglutide patients, compared to near-zero in placebo groups. While the absolute risk is low, the consequences of pancreatitis are severe enough that prior history is a hard disqualifier.

Your doctor will ask about any history of abdominal pain that required hospitalisation, gallstone pancreatitis, or alcohol-related pancreatic episodes.

Pregnancy and breastfeeding

GLP-1 medications are not safe during pregnancy. Animal studies show potential embryofetal toxicity, and no human trials have been conducted for ethical reasons.

If you are planning to conceive, you should stop GLP-1 treatment at least two months before trying to get pregnant. This gives the medication enough time to clear your system. Semaglutide has a half-life of about one week, so the two-month buffer provides several half-lives of clearance.

If you discover you are pregnant while on GLP-1 medication, stop immediately and contact your doctor.

For breastfeeding, there is no data on whether semaglutide or tirzepatide pass into breast milk. Because the safety profile is unknown, most doctors advise against using GLP-1 medications while nursing.

End-stage kidney disease

Patients with an eGFR below 15 mL/min/1.73m2 or those on dialysis cannot use GLP-1 medications. Clinical trials excluded patients with severe kidney impairment because there is insufficient data on drug clearance and safety in this population.

Additionally, GLP-1 side effects like nausea, vomiting, and diarrhoea can cause dehydration, which puts already-compromised kidneys under further strain.

This applies to end-stage disease specifically. Mild to moderate kidney impairment is handled differently (see the conditional disqualifiers section below).

Conditional disqualifiers: eligible with extra monitoring

These conditions do not automatically rule you out, but they require your doctor to prescribe with more caution, adjust doses, or monitor you more closely.

Chronic kidney disease (mild to moderate)

If your eGFR is 30 mL/min/1.73m2 or above, GLP-1 treatment can proceed with regular kidney function monitoring. Most GLP-1 medications do not require dose adjustments at this level, but your doctor should check kidney function at baseline and during follow-ups, especially after dose increases or if you experience vomiting or diarrhoea (which can cause dehydration and worsen kidney function).

Liver disease

Non-alcoholic fatty liver disease (NAFLD/MASLD) with normal liver function tests is not a disqualifier. In fact, some research suggests GLP-1 medications may improve liver fat. However, moderate to severe cirrhosis requires extra caution due to altered drug metabolism and the risk of liver decompensation. Your doctor should run baseline liver function tests (ALT, AST, bilirubin, albumin) and monitor during treatment.

Gallbladder history

A history of gallstones or gallbladder inflammation does not prevent GLP-1 use, but it increases the need for monitoring. Rapid weight loss on any treatment, not just GLP-1, increases gallstone risk. In the STEP semaglutide trials, gallbladder-related events occurred in 2.6% of patients versus 1.2% in the placebo group.

Your doctor will review your gallbladder history and advise you to watch for warning signs: sharp pain in the upper right abdomen, fever, or yellowing of skin or eyes. If you still have your gallbladder and have a history of gallstones, an ultrasound before starting treatment may be recommended.

Use with insulin or sulfonylureas

GLP-1 medications alone carry a very low risk of hypoglycaemia because they stimulate insulin in a glucose-dependent way (only when blood sugar is elevated). But combining GLP-1 with insulin or sulfonylureas like glipizide, gliclazide, or glimepiride increases hypoglycaemia risk significantly.

If you are already taking these medications for type 2 diabetes, your doctor will likely reduce the dose of your insulin or sulfonylurea when starting GLP-1 treatment. For basal insulin, a 10-20% reduction at initiation is common. You may also need to monitor blood glucose more frequently during the first few weeks.

Severe gastroparesis

GLP-1 medications slow gastric emptying as part of their mechanism. For most people, this causes manageable side effects like mild nausea or constipation. But if you already have severe gastroparesis (a condition where the stomach empties very slowly), GLP-1 medication can make symptoms significantly worse. Mild gastroparesis may be manageable with close monitoring, but severe cases are usually a disqualifier.

BMI eligibility in Singapore

Beyond medical conditions, you also need to meet BMI thresholds to qualify for GLP-1 treatment.

MOH Clinical Practice Guidelines:
- BMI 30 or above: eligible for pharmacotherapy without other conditions
- BMI 27.5-29.9: eligible with weight-related comorbidities (type 2 diabetes, hypertension, dyslipidaemia, sleep apnoea, PCOS, NAFLD)

Trimly's eligibility criteria:
- BMI 27.5 or above without weight-related conditions
- BMI 24 or above with conditions like T2D, hypertension, or PCOS

For Asian populations, BMI thresholds are generally lower than Western guidelines because metabolic risk increases at lower BMI levels in Asian individuals. A woman who is 160cm tall would need to weigh around 70kg for a BMI of 27.5, or around 61kg for a BMI of 24.

If you are unsure about your BMI, your doctor will calculate it during your consultation using your height and weight.

What happens if you are not eligible

If your doctor determines that GLP-1 medication is not right for you, there are other options:

• Lifestyle programmes. Structured diet and exercise plans supervised by a doctor or dietitian. These remain the foundation of weight management regardless of medication use.
• Other weight loss medications. Depending on your specific disqualifiers, alternatives like naltrexone-bupropion (Contrave) may be appropriate. Each medication has its own eligibility criteria and contraindication profile.
• Specialist referral. For complex cases, your doctor can refer you to an endocrinologist, bariatric specialist, or dietitian for a more specialised assessment.

Your consultation fee is not wasted if you turn out to be ineligible. Understanding your health picture is valuable even if the outcome is a different treatment path.

How Trimly assesses eligibility

Every Trimly consultation starts with a thorough eligibility assessment. Your doctor reviews your BMI, medical history, current medications, and any conditions that fall into the absolute or conditional disqualifier categories above.

• Video consultations with licensed Singapore doctors who assess all contraindications and comorbidities before prescribing.
• If you are eligible, medication is delivered to your door with no clinic visits required.
• If you need extra monitoring (kidney function, liver tests, gallbladder screening), your doctor will explain what tests are needed and how often.
• Unlimited free follow-ups throughout treatment for dose adjustments, side effect management, and progress reviews.

Treatment plans range from $350 to $650 per month, covering consultation, medication, delivery, and all follow-ups. Learn more about what doctors check before prescribing GLP-1.

Frequently asked questions

Can I take Ozempic if I have thyroid problems?

It depends on the type. The contraindication is specifically for medullary thyroid carcinoma (MTC) and MEN2 syndrome. If you have had papillary or follicular thyroid cancer, or hypothyroidism (underactive thyroid), these are not contraindications for GLP-1 medications. However, you should always disclose your thyroid history to your doctor so they can assess your individual risk.

Is GLP-1 medication safe if I have mild kidney disease?

In most cases, yes. Patients with an eGFR of 30 or above can typically use GLP-1 medications with regular kidney function monitoring. Your doctor should check eGFR at baseline and periodically during treatment, especially during dose increases. The disqualifier applies to end-stage kidney disease (eGFR below 15 or dialysis).

Can I take GLP-1 if I am on metformin?

Yes. Metformin and GLP-1 medications can be used together safely. Metformin does not increase hypoglycaemia risk the way insulin or sulfonylureas do, so no special dose adjustments are needed. Many patients with type 2 diabetes take both medications concurrently.

What should I tell my doctor during my eligibility assessment?

Be thorough about your medical history. Specifically mention any history of thyroid cancer (and the type), pancreatitis, gallbladder problems, kidney or liver disease, eating disorders, and all medications you currently take, including over-the-counter supplements. If you are pregnant, planning pregnancy, or breastfeeding, mention this as well. The more information your doctor has, the better the treatment decision.

Key takeaways

Most people who are interested in GLP-1 treatment are eligible. The absolute disqualifiers, medullary thyroid cancer history, pancreatitis, pregnancy, and end-stage kidney disease, affect a small percentage of patients. Conditional disqualifiers like mild kidney disease, liver conditions, or concurrent diabetes medications do not prevent treatment but do require extra monitoring. If you are unsure, a doctor consultation is the only reliable way to determine your eligibility.